Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 16, 2026
Strive Inc. (ASST) Stock Climbs +109% as Bitcoin Treasury Strategy Gains Momentum

Strive Inc. (ASST) Stock Climbs +109% as Bitcoin Treasury Strategy Gains Momentum

Key Takeaways

  • ASST shares roughly doubled over the trailing 30 days, climbing from about $13.20 to $27.57 as of the latest close, a gain of approximately 109%.
  • The rally reflects Strive's aggressive Bitcoin treasury strategy, with holdings reaching roughly 25,000 BTC and making it one of the largest public bitcoin holders.
  • Funding has come mainly from the company's SATA perpetual preferred stock, which crossed approximately $1 billion in notional value while keeping the balance sheet effectively debt-free.
  • The advance pushed shares above the $27 exercise price on more than $700 million of warrants expiring in mid-October, a key near-term catalyst.
  • Despite the surge, shares remain well below their 52-week high, underscoring the volatility of the bitcoin-treasury sector.

Strive Inc. (ASST) Background and Current Positioning

Strive, Inc. (formerly Asset Entities Inc.) is a Dallas, Texas-based company that transformed into a Bitcoin treasury company following its 2025 business combination. Founded in 2022 by Vivek Ramaswamy as an asset manager, Strive operates across two segments: Asset Management, which generates advisory fees from exchange-traded funds, collective investment trusts, and a direct indexing platform, and Corporate & Other, which houses its Bitcoin treasury. Under CEO Matt Cole, the company has positioned itself as a debt-free accumulator of Bitcoin, funding purchases primarily through preferred equity rather than convertible debt. Investors follow ASST as a leveraged proxy for Bitcoin prices and as a play on the broader institutional adoption of bitcoin-treasury strategies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ASST Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ASST advanced approximately 109%, rising from a closing price near $13.20 to about $27.57 as of the most recent session. The move was steep and sustained, with the stock setting a year-to-date high above $29 during the period before easing slightly.

The longer three-month view tells a similar but more volatile story. About a quarter earlier, shares traded near $15.79, meaning the stock has gained roughly 75% over that stretch. The quarter was not a straight line: shares touched a mid-June high above $16, pulled back below $11 in late June, consolidated through July, and then accelerated sharply in late August and September as Bitcoin purchases intensified. The recent 30-day surge accounts for the bulk of the quarterly gain. From what I see, this pattern highlights how quickly sentiment can shift in the bitcoin-treasury space.

Drivers Behind the Recent 30-Day Advance

The primary catalyst behind the 30-day advance was Strive's stepped-up Bitcoin accumulation. The company purchased 3,156 BTC in August alone, versus 136 BTC in July, then disclosed a 1,375 BTC acquisition between late August and early September at a cost of roughly $109 million, followed by an additional 469 BTC purchased in early-to-mid September. These moves lifted total holdings to about 25,000 BTC and pushed Strive past crypto exchange Bullish to become the fifth-largest public bitcoin-treasury company, while its market capitalization surpassed that of Japan-based Metaplanet.

Financing also fueled sentiment. Strive's SATA perpetual preferred stock, which pays a 13% annualized dividend daily and trades near its $100 par value, crossed roughly $1 billion in notional value outstanding, providing a steady capital pipeline without adding debt. Meanwhile, a rising Bitcoin price—which briefly traded above $82,000 before settling in the mid-to-high $70,000s—supported the valuation of the treasury. The rally also carried shares above the $27 exercise price on more than $700 million of warrants expiring in mid-October, raising the prospect of additional capital for future purchases. Analyst attention, including a raised year-end Bitcoin forecast and price target from TD Cowen, added to positive momentum. I’m watching this closely as the warrant expiration approaches.

Quarterly Performance Drivers

The quarterly move reflects Strive's broader pivot into a Bitcoin treasury model rather than any single event. Since the business combination and rebranding, management has prioritized rapid, debt-free Bitcoin accumulation through its SATA at-the-market issuance engine, which allows continuous capital raising while the preferred shares trade at or above par. Bitcoin's recovery from mid-year levels and growing investor appetite for bitcoin-treasury equities lifted the entire peer group, with Strive outperforming many larger holders on a percentage basis. The company's climb up the public-holder rankings, combined with its zero-debt balance sheet and expanding preferred-stock capacity, shaped a multi-month narrative of accelerating treasury growth that culminated in the recent surge.

Factors to Watch Going Forward

Several factors could shape ASST shares going forward. The most immediate is the mid-October expiration of more than $700 million in warrants with a $27 exercise price; whether they convert will determine how much fresh capital Strive can deploy into Bitcoin. Bitcoin price movements will also directly influence the value of the treasury and investor sentiment, while the sustainability of SATA issuance at or near par will govern the pace of future purchases. Investors should monitor the rate of Bitcoin accumulation and Strive's progress up the public-holder rankings, as well as quarterly results and advisory-fee trends in the asset-management segment. Valuation remains stretched, with a price-to-sales ratio well above historical levels and persistent operating losses, so risk considerations include Bitcoin volatility, dilution, preferred-dividend obligations, and the evolving regulatory environment for digital assets.

Exploring Automated Strategies with Tickeron

In my analysis, I often review Tickeron’s Trending AI Robots to see how different automated approaches are performing across tickers like ASST. The page curates top bots with varying strategies and timeframes, offering a data-driven way to compare options that might align with specific objectives. This helps me evaluate systematic ideas without committing capital right away.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ASST

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ASST's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for ASST moved out of overbought territory on September 25, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 instances where the indicator moved out of the overbought zone. In 19 of the 19 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 19 of 21 cases where ASST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASST as a result. In 58 of 62 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for ASST turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In 23 of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The 50-day moving average for ASST moved above the 200-day moving average on September 04, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASST advanced for three days, in 133 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

The Aroon Indicator entered an Uptrend today. In 60 of 69 cases where ASST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ASST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.382) is normal, around the industry mean (3.242). P/E Ratio (0.000) is within average values for comparable stocks, (26.802). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.341). ASST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.081). ASST's P/S Ratio (113.636) is very high in comparison to the industry average of (15.853).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Ares Capital Corp (NASDAQ:ARCC), WisdomTree (NYSE:WT), AMTD IDEA Group (NYSE:AMTD).

Industry description

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

Market Cap

The average market capitalization across the Investment Managers Industry is 8.63B. The market cap for tickers in the group ranges from 57 to 165.9B. BLK holds the highest valuation in this group at 165.9B. The lowest valued company is RSERF at 57.

High and low price notable news

The average weekly price growth across all stocks in the Investment Managers Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 8%. SDEV experienced the highest price growth at 151%, while INV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Investment Managers Industry was 35%. For the same stocks of the Industry, the average monthly volume growth was 93% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 30
P/E Growth Rating: 53
Price Growth Rating: 55
SMR Rating: 67
Profit Risk Rating: 81
Seasonality Score: 38 (-100 ... +100)
View a ticker or compare two or three
ASST
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry InvestmentManagers

Industry
N/A
Address
200 Crescent Court
Phone
+1 855 427-7360
Employees
28
Web
https://www.strive.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.